About Integrin beta-like protein 1
Integrin beta-like protein 1 (ITGBL1) is a protein
from Homo sapiens identified by UniProt accession
O95965, 494 residues long.
MolForge cross-references it against 0 known binders and
79 disease associations.
Target properties
| Protein name | Integrin beta-like protein 1 |
| UniProt accession | O95965 |
| Gene | ITGBL1 |
| Organism | Homo sapiens |
| Length | 494 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (79)
Diseases linked to this target (Open Targets).
- body height · score 0.30
- gonorrhea · score 0.10
- neoplasm · score 0.10
- hepatocellular carcinoma · score 0.09
- pachyonychia congenita · score 0.08
- drug use measurement · score 0.05
- laryngotracheoesophageal cleft · score 0.05
- hypertriglyceridemia 2 · score 0.05
- cholesterol-ester transfer protein deficiency · score 0.05
- cancer · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O95965-F1 | alphafold | PREDICTED | 84.46 | — |
Amino-acid sequence (494 residues)
MRPPGFRNFL LLASSLLFAG LSAVPQSFSP SLRSWPGAAC RLSRAESERR CRAPGQPPGA ALCHGRGRCD CGVCICHVTE PGMFFGPLCE CHEWVCETYD GSTCAGHGKC DCGKCKCDQG WYGDACQYPT NCDLTKKKSN QMCKNSQDII CSNAGTCHCG RCKCDNSDGS GLVYGKFCEC DDRECIDDET EEICGGHGKC YCGNCYCKAG WHGDKCEFQC DITPWESKRR CTSPDGKICS NRGTCVCGEC TCHDVDPTGD WGDIHGDTCE CDERDCRAVY DRYSDDFCSG HGQCNCGRCD CKAGWYGKKC EHPQSCTLSA EESIRKCQGS SDLPCSGRGK CECGKCTCYP PGDRRVYGKT CECDDRRCED LDGVVCGGHG TCSCGRCVCE RGWFGKLCQH PRKCNMTEEQ SKNLCESADG ILCSGKGSCH CGKCICSAEE WYISGEFCDC DDRDCDKHDG LICTGNGICS CGNCECWDGW NGNACEIWLG SEYP
Explore Integrin beta-like protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets